Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Simard

Showing results (171-180 of 177) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 177 results.
Cancer Research|January 28, 2010
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutationMartin L Sos, Haridas B Rode, Stefanie Heynck, et al.
Plos One|July 15, 2011
SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophyJohn T Kissel, Charles B Scott, Sandra P Reyna, et al.
Muscle & Nerve|May 18, 2013
SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophyJohn T Kissel, Bakri Elsheikh, Wendy M King, et al.
Journal of Medicinal Chemistry|December 22, 2016
The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine ReceptorsHoward Bregman, Jeffrey R Simard, Kristin L Andrews, et al.
Muscle & Nerve|August 24, 2017
Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type IKristin J Krosschell, John T Kissel, Elise L Townsend, et al.
Cancer Research|October 28, 2025
CFT1946 is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader that Overcomes BRAF Inhibitor ResistanceBridget T Kreger, Yanke Liang, Nicole M Reilly, et al.
Cancer Discovery|February 14, 2012
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancerPeter S Hammerman, Martin L Sos, Alex H Ramos, et al.
Pageof 18

Showing results (171-180 of 177) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 177 results.
Cancer Research|January 28, 2010
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutationMartin L Sos, Haridas B Rode, Stefanie Heynck, et al.
Plos One|July 15, 2011
SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophyJohn T Kissel, Charles B Scott, Sandra P Reyna, et al.
Muscle & Nerve|May 18, 2013
SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophyJohn T Kissel, Bakri Elsheikh, Wendy M King, et al.
Journal of Medicinal Chemistry|December 22, 2016
The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine ReceptorsHoward Bregman, Jeffrey R Simard, Kristin L Andrews, et al.
Muscle & Nerve|August 24, 2017
Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type IKristin J Krosschell, John T Kissel, Elise L Townsend, et al.
Cancer Research|October 28, 2025
CFT1946 is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader that Overcomes BRAF Inhibitor ResistanceBridget T Kreger, Yanke Liang, Nicole M Reilly, et al.
Cancer Discovery|February 14, 2012
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancerPeter S Hammerman, Martin L Sos, Alex H Ramos, et al.
Pageof 18